Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.55 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.50 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272992 | 1.00 | CTSB (0.55) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13522781 | 1.00 | CTSB (0.55) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL8274106 | 1.00 | CTSB (0.55) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10193686 | 0.95 | CTSB (0.54) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL8274031 | 0.94 | CTSB (0.53) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL8276293 | 0.94 | CTSB (0.53) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL10221250 | 0.92 | CTSB (0.47) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13083030 | 0.92 | CTSB (0.47) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13223026 | 0.92 | CTSB (0.47) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL8273160 | 0.88 | CTSB (0.60) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2316839-B1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS HAVING PHOSPHONATE GROUPS | GILEAD SCIENCES INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8586744-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2043658-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2422791-A1 | Antiviral phosphinate compounds | Gilead Sciences, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1778702-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2316839-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7893264-B2 | viricides comprising phosphinic acid compounds and/or mixed with carriers, nucleoside analogues, interferons or pegylated interferons; treating hepatitis C or a hepatitis C associated disorders in animals; side effect reduction | GILEAD SCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7642339-B2 | Hepatitis C; 1-benzyloxycarbonylamino-2-vinyl-cyclopropyl)-phenyl-phosphinic acid ethyl ester | GILEAD SCIENCES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2043658-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080057031-A1 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008005565-A2 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1778702-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122123-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006020276-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080057031-A1 | Antiviral phosphinate compounds | PHOSPHO1, MAVS, ITPA | CTSB 1737/4885PPP3CB 149/4885ABCC1 2724/4885 |
| US-20090227491-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | CTSB 1737/4885PPP3CB 149/4885ABCC1 2724/4885 |
| US-20110081314-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | PHOSPHO1, MAVS, ITPA | CTSB 1737/4885PPP3CB 149/4885ABCC1 2724/4885 |
| US-20080311077-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | CTSB 1150/4885PPP3CB 292/4885ABCC1 2032/4885 |
| US-20060122123-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | CTSB 1150/4885PPP3CB 292/4885ABCC1 2032/4885 |
| US-20110082112-A1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | HAVCR2, PHOSPHO1, EIF2AK2 | CTSB 830/4885PPP3CB 30/4885ABCC1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.